Status:
COMPLETED
Intralesional Triamcinolone Acetonide and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars
Lead Sponsor:
B.P. Koirala Institute of Health Sciences
Collaborating Sponsors:
Nepal Health Research Council
Conditions:
Scar Keloid
Eligibility:
All Genders
16+ years
Phase:
NA
Brief Summary
Summary: Keloids and hypertrophic scars are benign fibrous growth, differing mainly by overgrowth beyond the initial defect in keloid whereas hypertrophic scar is confined to initial lesion and tends ...
Detailed Description
HYPOTHESIS Null hypothesis: There is no difference in the efficacy of intralesional triamcinolone acetonide alone and its combination with 5-flurouracil in the treatment of keloids and hypertrophic sc...
Eligibility Criteria
Inclusion
- Patient with clinically diagnosed keloid or hypertrophic scar
- Size of scar 1cm in length or more
- Informed consent given
Exclusion
- Under treatment of keloids or hypertrophic scar in past 6 months
- Patient with renal disease
- Patient with liver disease
- History of Hypersensitivity to 5-fluorouracil or triamcinolone acetonide
- Immunosuppressed conditions: HIV, Immunosuppressive therapy, Uncontrolled diabetes
- Pregnant or lactating women or patient planning for pregnancy
- Open wound in the scar
- Atrophic scar
- Patients suffering from chronic infectious conditions like Tuberculosis
- Patients with low WBC count
Key Trial Info
Start Date :
January 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 14 2021
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04812626
Start Date
January 28 2021
End Date
September 14 2021
Last Update
April 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
B.P. Koirala Institute of Health Sciences
Dharān, Province No. 1, Nepal, 025